Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Torcetrapib Phase III Program Will Cost $800 Mil.

Executive Summary

Pfizer is spending $800 mil. on the Phase III development program for the cholesterol agent torcetrapib, Worldwide Development President Joe Feczko, MD, said during a Nov. 30 analysts meeting in Groton, Conn

You may also be interested in...



Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program

Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet

Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program

Pfizer’s Torcetrapib/Lipitor Raises HDL Cholesterol, But Blood Pressure Too

Apparent increases in systolic blood pressure caused by Pfizer's torcetrapib/Lipitor (atorvastatin) combination will be investigated in further clinical studies, the firm said

Related Content

Topics

UsernamePublicRestriction

Register

PS045072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel